Skip to main content
Clinical Trials/NCT02810262
NCT02810262CompletedNot Applicable

Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)

Hospices Civils de Lyon2 sites in 1 country200 target enrollmentStarted: June 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
200
Locations
2
Primary Endpoint
serum DKK1

Study Overview

Brief Summary

Mortality due to non small cell lung cancers is the first cause of cancer death in men around the world. Lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. Overall survival of these patients is poor. Thus the investigators aimed to identify if some bone and metabolic parameters were associated with overall survival.

Patients and Methods POUMOS is a prospective cohort of patients suffering from adenocarcinoma lung cancers with a first bone metastasis (stage IV). All patients have a bone biopsy with molecular status characterization of the tumor for EGFR, KRAS, BRAF and ALK. Bone metastasis localizations are obtained by bone scintigraphy or FDG-PET/CT. Whole body composition is obtained by DEXA scan (Hologic®). The investigators assessed also fasting blood levels of bone and metabolic biomarkers.

Survival analyses will be performed using a proportional hazard regression model.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • adults over 18 years
  • both gender
  • covered by the French National Insurance
  • first bone metastases of adenocarcinoma lung cancer (synchronous or metachrone)

Exclusion Criteria

  • - adenocarcinoma previously treated by systemic oncologic treatment (chemotherapy, targeted therapy, immunotherapy)

Outcomes

Primary Outcomes

serum DKK1

Time Frame: day 0

Biomarkers are assessed at baseline.

Secondary Outcomes

  • urinary CTX(day 0)
  • serum HbA1C(day 0)
  • mutational profile of the bone metastases(day 0)
  • hip bone mass (g/cm²)(day 0)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials